PTC Therapeutics, Inc. (PTCT) Earnings Call Transcripts
PTC Therapeutics, Inc.'s Latest Earnings Call - June 9, 2026
In Q1 2026, PTC Therapeutics reported record product revenue of $226 million and total revenue of $273 million, driven by the successful launch of Sephience. Management highlighted the ongoing momentum of Sephience, with expectations for continued growth in both the U.S. and international markets. The company also announced plans for several clinical trials, including the MOVE-FA trial for vatiquinone and a Phase IIa study for PTC844, indicating a robust pipeline that could enhance future revenue streams.
Reported metrics
| Metric | Value |
|---|---|
| Total Revenue | $273 million (beat) |
| Product Revenue | $226 million (beat) |
| Cash Balance | $1.9 billion (positive) |
| Global Market Opportunity for Sephience | $2 billion+ (positive) |
| Number of Prescribing Centers | 90% (positive) |
| FDA Trial Enrollment | 120 individuals (positive) |
Guidance from management
Management maintained a positive outlook for the remainder of 2026, expecting continued growth from Sephience and advancements in their R&D pipeline. They did not provide specific revenue guidance but emphasized the potential for significant market opportunities ahead.
What management said
Yes. And it makes perfect sense. This is a community that PKU patients, their daily life is combo cocktail therapy. That's how they live today. And so it's not surprising if you can have additional therapies that can get you even more benefit, that would be the ideal.
Yes. So clearly, having a product like Sephience that can be a multibillion-dollar rare disease product, the fact that we have a robust pipeline with the leading oral HD therapy in development with none of the costs but a significant back end, the ability to innovate and have a steady flow of pipeline assets and then sitting in a strong cash position with over $1.9 billion gives us flexibility to continue to augment,...
What analysts pressed on
Analysts expressed concerns regarding the competitive landscape and potential pricing pressures from emerging therapies. There were also questions about the timeline for reimbursement discussions in key markets and how these could impact revenue projections.
Main topics on the call
- Sephience Launch Success — Management expressed excitement about the Sephience launch, stating that over '90% of the centers of excellence in the U.S. have already prescribed Sephience.' They anticipate continued growth in both the U.S. and intern...
- Market Opportunity Expansion — PTC Therapeutics now estimates a 'global opportunity' for Sephience exceeding $2 billion, driven by its ability to address a wide range of PKU patients. Management emphasized that Sephience's differentiated profile allow...
- FDA Alignment for Vatiquinone — Management noted a positive shift in FDA dialogue regarding vatiquinone, stating that the agency suggested an 'open-label natural history comparator study' for additional data to support NDA resubmission. This change ref...
- Pipeline Development — PTC plans to initiate several clinical trials, including the MOVE-FA trial for Friedreich's ataxia and a Phase IIa study for PTC844. Management highlighted the potential for these programs to drive future revenue growth,...
Read the full PTC Therapeutics, Inc. transcript (June 9, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About PTC Therapeutics, Inc.
PTC Therapeutics, Inc. (PTCT) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 95 calls on record spanning January 15, 2020 to July 30, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 95 PTC Therapeutics, Inc. earnings call transcripts on record, spanning January 15, 2020 to July 30, 2026. Based on this history, PTC Therapeutics, Inc. reports quarterly. The most recent call on file is dated July 30, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- PTCT
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 95
- First call
- January 15, 2020
- Most recent
- July 30, 2026
- Reporting cadence
- quarterly